Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: April 12, 2005
Last updated: May 20, 2015
Last verified: May 2015